Kronos Bio faces extreme financial challenges, leading to an 83% layoff and discontinuation of its only clinical-stage drug due to severe side effects.
The oncology research firm reported a staggering accumulated deficit of $508 million, raising concerns about its future following significant losses and setbacks in clinical trials.
Collection
[
|
...
]